American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer

Gary H. Lyman, Alok A. Khorana, Anna Falanga, Daniel Clarke-Pearson, Christopher Flowers, Mohammad Jahanzeb, Ajay Kakkar, Nicole M. Kuderer, Mark N. Levine, Howard Liebman, David Mendelson, Gary Raskob, Mark R. Somerfield, Paul Thodiyil, David Trent, Charles W. Francis

Research output: Contribution to journalArticle

779 Citations (Scopus)

Abstract

Purpose: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. Methods: A comprehensive systematic review of the medical literature on the prevention and treatment of VTE in cancer patients was conducted and reviewed by a panel of content and methodology experts. Following discussion of the results, the panel drafted recommendations for the use of anticoagulation in patients with malignant disease. Results: The results of randomized controlled trials of primary and secondary VTE medical prophylaxis, surgical prophylaxis, VTE treatment, and the impact of anticoagulation on survival of patients with cancer were reviewed. Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival. Conclusion: Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the absence of bleeding or other contraindications; (2) routine prophylaxis of ambulatory cancer patients with anticoagulation is not recommended, with the exception of patients receiving thalidomide or lenalidomide; (3) patients undergoing major surgery for malignant disease should be considered for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred agent for both the initial and continuing treatment of cancer patients with established VTE; and (5) the impact of anticoagulants on cancer patient survival requires additional study and cannot be recommended at present.

Original languageEnglish
Pages (from-to)5490-5505
Number of pages16
JournalJournal of Clinical Oncology
Volume25
Issue number34
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Venous Thromboembolism
Guidelines
Neoplasms
Therapeutics
Anticoagulants
Survival
Thalidomide
Low Molecular Weight Heparin
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

American Society of Clinical Oncology Guideline : Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. / Lyman, Gary H.; Khorana, Alok A.; Falanga, Anna; Clarke-Pearson, Daniel; Flowers, Christopher; Jahanzeb, Mohammad; Kakkar, Ajay; Kuderer, Nicole M.; Levine, Mark N.; Liebman, Howard; Mendelson, David; Raskob, Gary; Somerfield, Mark R.; Thodiyil, Paul; Trent, David; Francis, Charles W.

In: Journal of Clinical Oncology, Vol. 25, No. 34, 01.12.2007, p. 5490-5505.

Research output: Contribution to journalArticle

Lyman, GH, Khorana, AA, Falanga, A, Clarke-Pearson, D, Flowers, C, Jahanzeb, M, Kakkar, A, Kuderer, NM, Levine, MN, Liebman, H, Mendelson, D, Raskob, G, Somerfield, MR, Thodiyil, P, Trent, D & Francis, CW 2007, 'American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer', Journal of Clinical Oncology, vol. 25, no. 34, pp. 5490-5505. https://doi.org/10.1200/JCO.2007.14.1283
Lyman, Gary H. ; Khorana, Alok A. ; Falanga, Anna ; Clarke-Pearson, Daniel ; Flowers, Christopher ; Jahanzeb, Mohammad ; Kakkar, Ajay ; Kuderer, Nicole M. ; Levine, Mark N. ; Liebman, Howard ; Mendelson, David ; Raskob, Gary ; Somerfield, Mark R. ; Thodiyil, Paul ; Trent, David ; Francis, Charles W. / American Society of Clinical Oncology Guideline : Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 34. pp. 5490-5505.
@article{ba2767557f7d4c39831e9c1b0836255c,
title = "American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer",
abstract = "Purpose: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. Methods: A comprehensive systematic review of the medical literature on the prevention and treatment of VTE in cancer patients was conducted and reviewed by a panel of content and methodology experts. Following discussion of the results, the panel drafted recommendations for the use of anticoagulation in patients with malignant disease. Results: The results of randomized controlled trials of primary and secondary VTE medical prophylaxis, surgical prophylaxis, VTE treatment, and the impact of anticoagulation on survival of patients with cancer were reviewed. Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival. Conclusion: Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the absence of bleeding or other contraindications; (2) routine prophylaxis of ambulatory cancer patients with anticoagulation is not recommended, with the exception of patients receiving thalidomide or lenalidomide; (3) patients undergoing major surgery for malignant disease should be considered for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred agent for both the initial and continuing treatment of cancer patients with established VTE; and (5) the impact of anticoagulants on cancer patient survival requires additional study and cannot be recommended at present.",
author = "Lyman, {Gary H.} and Khorana, {Alok A.} and Anna Falanga and Daniel Clarke-Pearson and Christopher Flowers and Mohammad Jahanzeb and Ajay Kakkar and Kuderer, {Nicole M.} and Levine, {Mark N.} and Howard Liebman and David Mendelson and Gary Raskob and Somerfield, {Mark R.} and Paul Thodiyil and David Trent and Francis, {Charles W.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1200/JCO.2007.14.1283",
language = "English",
volume = "25",
pages = "5490--5505",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "34",

}

TY - JOUR

T1 - American Society of Clinical Oncology Guideline

T2 - Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer

AU - Lyman, Gary H.

AU - Khorana, Alok A.

AU - Falanga, Anna

AU - Clarke-Pearson, Daniel

AU - Flowers, Christopher

AU - Jahanzeb, Mohammad

AU - Kakkar, Ajay

AU - Kuderer, Nicole M.

AU - Levine, Mark N.

AU - Liebman, Howard

AU - Mendelson, David

AU - Raskob, Gary

AU - Somerfield, Mark R.

AU - Thodiyil, Paul

AU - Trent, David

AU - Francis, Charles W.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. Methods: A comprehensive systematic review of the medical literature on the prevention and treatment of VTE in cancer patients was conducted and reviewed by a panel of content and methodology experts. Following discussion of the results, the panel drafted recommendations for the use of anticoagulation in patients with malignant disease. Results: The results of randomized controlled trials of primary and secondary VTE medical prophylaxis, surgical prophylaxis, VTE treatment, and the impact of anticoagulation on survival of patients with cancer were reviewed. Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival. Conclusion: Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the absence of bleeding or other contraindications; (2) routine prophylaxis of ambulatory cancer patients with anticoagulation is not recommended, with the exception of patients receiving thalidomide or lenalidomide; (3) patients undergoing major surgery for malignant disease should be considered for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred agent for both the initial and continuing treatment of cancer patients with established VTE; and (5) the impact of anticoagulants on cancer patient survival requires additional study and cannot be recommended at present.

AB - Purpose: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer. Methods: A comprehensive systematic review of the medical literature on the prevention and treatment of VTE in cancer patients was conducted and reviewed by a panel of content and methodology experts. Following discussion of the results, the panel drafted recommendations for the use of anticoagulation in patients with malignant disease. Results: The results of randomized controlled trials of primary and secondary VTE medical prophylaxis, surgical prophylaxis, VTE treatment, and the impact of anticoagulation on survival of patients with cancer were reviewed. Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival. Conclusion: Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the absence of bleeding or other contraindications; (2) routine prophylaxis of ambulatory cancer patients with anticoagulation is not recommended, with the exception of patients receiving thalidomide or lenalidomide; (3) patients undergoing major surgery for malignant disease should be considered for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred agent for both the initial and continuing treatment of cancer patients with established VTE; and (5) the impact of anticoagulants on cancer patient survival requires additional study and cannot be recommended at present.

UR - http://www.scopus.com/inward/record.url?scp=36849070772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849070772&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.14.1283

DO - 10.1200/JCO.2007.14.1283

M3 - Article

C2 - 17968019

AN - SCOPUS:36849070772

VL - 25

SP - 5490

EP - 5505

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 34

ER -